What are Lifecore Biomedical, Inc.'s total assets?

Lifecore Biomedical, Inc. (LFCR) holds $225.5M in total assets, down 5.8% year over year.

How much debt does Lifecore Biomedical, Inc. have?

Lifecore Biomedical, Inc. carries $156.9M in total debt against -$28.4M of shareholders' equity, a debt-to-equity ratio of 8.33.

How much cash does Lifecore Biomedical, Inc. have?

Lifecore Biomedical, Inc. holds $20.8M in cash and equivalents.

Can Lifecore Biomedical, Inc. cover its short-term obligations?

Its current ratio is 3.79 — current assets exceed current liabilities.

Where does Lifecore Biomedical, Inc.'s balance sheet data come from?

Every line is extracted from Lifecore Biomedical, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Lifecore Biomedical, Inc. LFCR Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q4 '26	TTM Q3 '26	TTM Q2 '26	TTM Q1 '26	TTM Q4 '25
Cash and cash equivalents	——	——	——	——	$8.27M+52.6%
Accounts receivable, net	——	——	——	——	$8M-20.0%
Inventories	——	——	——	——	$32.29M-6.7%
Raw materials	——	——	——	——	——
Work in process	——	——	——	——	——
Finished goods	——	——	——	——	——
Contract assets	$7.45M-2.7%	$7.66M+74.6%	$4.39M-51.4%	$9.03M+29.3%	$6.98M+13.5%
Total current assets	——	——	——	——	$85.68M+1.7%
Property and equipment, net	——	——	——	——	$129.01M+0.6%
Accumulated depreciation	——	——	——	——	——
Goodwill	——	——	——	——	$13.88M0.0%
Other non-current assets	——	——	——	——	$6.58M+288%
Total assets	——	——	——	——	$239.34M+0.7%
Accounts payable	——	——	——	——	$8.22M+11.0%
Accrued expenses	——	——	——	——	$21.96M+276%
Deferred revenue	——	——	——	——	——
Current portion of long-term debt	——	——	——	——	$3.44M+270%
Operating lease liabilities, current	——	——	——	——	——
Finance Lease Liability, Current	——	——	——	——	——
Total current liabilities	——	——	——	——	$30.18M-3.0%
Long-term debt	——	——	——	——	——
Operating lease liabilities, non-current	——	——	——	——	——
Finance Lease Liabilities (Total)	——	——	——	——	——
Operating Lease Liabilities (Total)	——	——	——	——	——
Finance lease liabilities	——	——	——	——	——
Other non-current liabilities	——	——	——	——	$9.74M-0.7%
Total liabilities	——	——	——	——	$191.91M+0.9%
Common stock	——	——	——	——	37K-100.0%
Additional paid-in capital	——	——	——	——	$206.54M+0.1%
Retained earnings	——	——	——	——	-$205.24M-0.6%
Redeemable noncontrolling interests	——	——	——	——	——
Total stockholders' equity	-$28.44M-100%	-$14.2M-34.8%	-$10.54M-1,124%	-$861K-164%	$1.34M-40.1%
Total liabilities and stockholders' equity	——	——	——	——	$239.34M+0.7%
Allowance for Doubtful Accounts	——	——	——	——	——
Allowance for Doubtful Accounts Receivable (Current)	——	——	——	——	——
Equipment Installment Plan Receivables, Gross	——	——	——	——	——
Financing Receivables	——	——	——	——	——
Deferred Tax Assets and Other Non-Current Assets	——	——	——	——	$6.58M+33.0%
Other non-current assets	——	——	——	——	$6.58M+33.0%
Property, plant and equipment at cost	——	——	——	——	——
Software and Technology Licenses, Net	——	——	——	——	$6.58M+33.0%
Accrued Manufacturing Costs	——	——	——	——	——
Other Commercial Liabilities	——	——	——	——	——
Convertible Debt - Current	——	——	——	——	——
Accrued Liabilities, Current	——	——	——	——	——
Compensation and benefits	——	——	——	——	——
Derivative Liabilities - Fair Value	——	——	——	——	$24.99M+4.6%
Finance Lease Liability Payment Due	——	——	——	——	——
Finance Lease Liability - Undiscounted Excess Amount	——	——	——	——	——
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——	——
Lease Liability Payments - 2021	——	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——	——
Lease Liability Payments - Due Year Four	——	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——	——
Professional Service Fees Payable	——	——	——	——	——
Debt Instrument Convertible Conversion Price	——	——	——	——	——
Debt Maturity - 2024	——	——	——	——	——
Debt Maturity - 2027	——	——	——	——	——
Debt - Unamortized Discount (Premium) and Issuance Costs, Net	——	——	——	——	——
Derivative Liabilities (Non-Current)	——	——	——	——	$24.99M+4.6%
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	——	——	——	——	——
Total debt	——	——	——	——	$11.13M-91.9%
Total Carrying Value of Debt	——	——	——	——	——
Common Stock Par Value Per Share	——	——	——	——	——
Common Stock Shares Issued	——	——	——	——	——
Common Stock Shares Outstanding	——	——	——	——	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	——	——	——	——	$37K0.0%
Number of Exercisable Options	——	——	——	——	——
Share-Based Payment Award Options Outstanding - Number	——	——	——	——	——
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——	——	——	——
Temporary Equity Attributable to Parent	——	——	——	——	——
Weighted Average Exercise Price of Outstanding Options	——	——	——	——	——
Nonperforming Loans and Leases Percentage	——	——	——	——	——
Fair Value Measurement Disclosure	——	——	——	——	——
Accrued Professional Fees Current And Noncurrent	——	——	——	——	——
Accounts Receivable, Allowance for Credit Loss	——	——	——	——	——
Common stock, par value (in dollars per share)	——	——	——	——	——
Common stock, shares authorized (in shares)	——	——	——	——	——
Common stock, shares issued (in shares)	——	——	——	——	——
Common Stock, Shares, Outstanding	——	——	——	——	——
Long-term debt, gross	——	——	——	——	——
Less: net unamortized discount	——	——	——	——	——
Derivative Liability, Noncurrent	——	——	——	——	$24.99M+4.6%
Unrecognized compensation cost related to non-vested awards	——	——	——	——	——
Current maturities of long-term debt	——	——	——	——	——
Finance Lease Liability Payments Due	——	——	——	——	——
2027	——	——	——	——	——
Finance Lease Liability Payments Due Year Four	——	——	——	——	——
Finance Lease Liability Payments Due Year Three	——	——	——	——	——
Finance Lease Liability Payments Due Year Two	——	——	——	——	——
Thereafter	——	——	——	——	——
Finance Lease Liability Undiscounted Excess Amount	——	——	——	——	——
Financing receivable, unamortized purchase discount	——	——	——	——	——
Note receivable, variable interest rate	——	——	——	——	——
Raw materials	——	——	——	——	——
Number of active facilities	——	——	——	——	——
Lessee Operating Lease Liability Payments Due	——	——	——	——	——
Thereafter	——	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——	——
2028	——	——	——	——	——
2029	——	——	——	——	——
2030	——	——	——	——	——
2027	——	——	——	——	——
Remainder of 2026	——	——	——	——	——
Thereafter	——	——	——	——	——
Other accrued liabilities	——	——	——	——	——
Convertible preferred stock, shares issuable upon conversion (in shares)	——	——	——	——	——
Preferred stock, stock price threshold (in dollars per share)	——	——	——	——	——
Preferred stock, unpaid balance, interest rate	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	——	——	——	——	——
Temporary equity, directors, stock outstanding threshold	——	——	——	——	——
Temporary Equity Liquidation Preference	——	——	——	——	——
Preferred stock Series C, liquidation preference (in dollars per share)	——	——	——	——	——
Temporary equity, number of directors	——	——	——	——	——
Temporary Equity Par Or Stated Value Per Share	——	——	——	——	——
Temporary Equity Shares Authorized	——	——	——	——	——
Temporary Equity Shares Issued	——	——	——	——	——
Temporary Equity Shares Outstanding	——	——	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Lifecore Biomedical, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Lifecore Biomedical, Inc.'s total assets?: Lifecore Biomedical, Inc. (LFCR) holds $225.5M in total assets, down 5.8% year over year.
How much debt does Lifecore Biomedical, Inc. have?: Lifecore Biomedical, Inc. carries $156.9M in total debt against -$28.4M of shareholders' equity, a debt-to-equity ratio of 8.33.
How much cash does Lifecore Biomedical, Inc. have?: Lifecore Biomedical, Inc. holds $20.8M in cash and equivalents.
Can Lifecore Biomedical, Inc. cover its short-term obligations?: Its current ratio is 3.79 — current assets exceed current liabilities.
Where does Lifecore Biomedical, Inc.'s balance sheet data come from?: Every line is extracted from Lifecore Biomedical, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.